Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Discover why Denali Therapeutics Inc. earns a Strong Buy with FDA-priority drugs, solid pipeline, and a strong cash position.
Precision Medicine Online

Hunter Syndrome Gene Therapy Improves Key Disease Enzyme in First Treated Patients in UK

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Couple struggling to access 'vital' cancer drug

A couple struggling to access a vital cancer treatment say they are "extremely stressed" by the uncertainty in its supply.

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

Denali makes $275m funding agreement with Royalty Pharma

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
Fierce Biotech

FDA slaps hold on Denali's plans for phase 1 rare disease trial

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
Fierce Biotech

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
TipRanks on MSN

Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement

Royalty Pharma (RPRX) and Denali Therapeutics (DNLI) announced a $275M synthetic royalty funding agreement based on future net sales of ...

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic ...
Smithsonian Magazine

This Toddler Was the First Person to Receive a Test Treatment for a Rare Genetic Disorder. Nine Months Later, His Progress Is Inspiring Hope

Oliver Chu is one of five kids participating in a clinical trial investigating a gene therapy for Hunter syndrome, a disorder with symptoms akin to childhood dementia that limits life expectancy ...
MyHorryNews

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA ...

FDA Flags Antibody Risk After Child's Death Linked To Takeda's Enzyme Replacement Therapy For Rare Blood Disorder

FDA reports rare neutralizing antibodies, including a pediatric death, in patients treated with Takeda's Adzynma for congenital TTP.